OBiO Technology Shanghai Corp., established in March 2013, specializes in the development and incubation of gene therapy drugs, particularly for cancer treatment. The company operates in the biotechnology sector, serving pharmaceutical companies and research institutions. OBiO has secured over 100 million RMB in equity financing and is listed on the NEEQ Market under the stock name Heyuan Shanghai, ID 839702. Over the past five years, the company has achieved an average annual sales revenue growth rate exceeding 50%.

OBiO's business model focuses on providing comprehensive services from lab-scale process development to clinical phase III trials. The company generates revenue through research and development contracts, pilot production, and the sale of GMP-grade materials. OBiO boasts a state-of-the-art 6,000 square meter facility for R&D, pilot production, and business operations. The company holds 12 authorized invention patents and has several patents under examination in China, the United States, Japan, and Australia.

The company's core competencies include preclinical PK/PD/Tox studies in GLP labs, assay method qualification or validation, and scaling up processes in class C/D pilot plants. OBiO is equipped with global standard equipment to ensure high-quality experiments, operations, and tests in both lab and GMP plant settings. The company also specializes in plasmid purification by chromatography and UF/DF, and has developed assay methods for various viruses, including Adeno-associated virus (AAV), Lentivirus (LV), Adenovirus (ADV), Retrovirus (RV), Herpes simplex virus (HSV), and other oncolytic viruses.

OBiO serves a diverse clientele, including pharmaceutical companies and research institutions, by providing small-scale virus production for drug studies and E. coli fermentation process development to improve plasmid titer.

Keywords: gene therapy, cancer treatment, biotechnology, R&D, GMP manufacturing, virus assay, plasmid purification, equity financing, NEEQ Market, global standard equipment.